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Abstract  30 
Background 31 
Mitigating the socioeconomic impact of tuberculosis is key to the WHO End TB Strategy. However, 32 
little known about socioeconomic wellbeing beyond TB-treatment completion. In this mixed-methods 33 
study we describe socioeconomic outcomes after TB-disease in urban Blantyre, Malawi, and explore 34 
pathways and barriers to financial recovery. 35 
Methods 36 
Adults ≥15 years successfully completing treatment for a first episode of pulmonary TB under the 37 
National TB Control Programme were prospectively followed-up for 12-months. Socioeconomic, 38 
income, occupation, health-seeking and cost data were collected. Determinants and impacts of 39 
ongoing financial hardship were explored through illness narrative interviews with purposively 40 
selected participants. 41 
Results 42 
405 participants were recruited from February 2016 - April 2017. Median age was 35-years (IQR: 28-43 
41), 67.9% (275/405) were male, and 60.6% (244/405) were HIV-positive. Employment and incomes 44 
were lowest at TB-treatment completion, with limited recovery in the following year: fewer people 45 
were in paid work (63.0% [232/368] vs. 72.4% [293/405], p=0.006), median incomes were lower 46 
($44.13 [IQR: $0-106.15] vs. $72.20 [IQR: $26.71-173.29], p<0.001), and more patients were living in 47 
poverty (earning <$1.90/day: 57.7% [211/366] vs. 41.6% [166/399], p<0.001) 1-year after TB-48 
treatment completion compared to before TB-disease onset. Half of the participants (50.5%, 184/368) 49 
reported ongoing dissaving (use of savings, selling assets, borrowing money) and 9.5% (35/368) 50 
reported school interruptions in the year after TB-treatment completion. Twenty-one participants 51 
completed in-depth interviews. Reported barriers to economic recovery included financial insecurity, 52 
challenges rebuilding business relationships, residual physical morbidity, and stigma.  53 
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Conclusions 54 
TB-affected households remain economically vulnerable even after TB-treatment completion, with 55 
limited recovery in income and employment , persistent financial strain requiring dissaving, and school 56 
interruptions. Measures of the economic impact of TB-disease should include the post-TB period. 57 
Interventions to protect the long-term health and livelihoods of TB survivors must be explored.  58 
 59 
Key words: Pulmonary tuberculosis, TB sequelae, post-TB lung disease, health economics, social 60 
determinants  61 
 62 
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Key messages 64 
What is the key question? 65 
What is the lasting socioeconomic impact of TB-disease on patients and households: can we assume 66 
full economic recovery after successful treatment completion, and what are the pathways and barriers 67 
to this recovery? 68 
What is the bottom line? 69 
Many TB-affected households experience a limited recovery in income and employment in the year 70 
after TB-treatment completion, with ongoing dissaving and school interruptions. Barriers to economic 71 
recovery include persistent financial insecurity, challenges rebuilding business relationships, residual 72 
physical morbidity, and stigma.  73 
Why read on? 74 
The socioeconomic impact of TB disease persists well beyond TB treatment completion – 75 
understanding this process, and developing strategies to mitigate this, will be crucial if we are to meet 76 
the WHO End TB  Strategy target of eliminating TB-related catastrophic costs by 2030, and improve 77 
the long-term wellbeing of TB survivors.  78 
 79 
 80 
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Introduction 88 
An estimated 10 million incident cases of tuberculosis (TB) disease occurred globally in 2018, one 89 
quarter of which occurred in Africa where 29% of patients are HIV co-infected.(1) The early costs 90 
associated with TB-disease in low-income settings are well recognised: despite provision of free TB-91 
treatment services within the public sector, patients incur direct costs related to health seeking, 92 
indirect costs from lost income, and dissaving (the use of savings, borrowing of money, or sale of 93 
household assets) over the course of illness, diagnosis, and treatment.(2, 3) These early costs are 94 
widespread, frequently profound, and have been associated with adverse TB-treatment outcomes 95 
including treatment failure, loss to follow-up or death.(4)  However surprisingly little is known about 96 
the lasting economic impact of disease beyond TB-treatment completion, and facilitators or barriers 97 
to economic recovery.  98 
The physical effects of pulmonary-TB (PTB) are felt long after treatment completion: mortality rates 99 
are three to four fold higher amongst TB survivors compared to TB-naïve adults,(5) TB survivors have 100 
a high risk of disease recurrence,(6) and the burden of residual post-TB lung disease (PTLD) is 101 
marked.(7, 8) Limited data are available on long-term psychosocial morbidities, but reports from TB-102 
affected communities suggest these are considerable.(9, 10) It is plausible that the ongoing physical 103 
and psychosocial impact of TB disease is accompanied by long-term economic harm. Understanding 104 
this link will be key to improving the overall wellbeing of TB survivors,(11, 12) and essential if we are 105 
to meet the WHO End TB Strategy target of eliminating catastrophic costs for all TB-affected 106 
households by 2030.(13)   107 
Malawi is one of the poorest countries in the world,(14) with an estimated national TB incidence of 108 
181/100,000 in 2018.(15) In this mixed-methods study, nested within a prospective cohort of adults 109 
successfully treated for PTB in urban Blantyre, Malawi,(16) we describe economic morbidity in the 110 
year after TB-treatment completion, and explore its determinants and impacts. 111 
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Methods 112 
Full methods of the parent cohort study have been described previously.(16) In brief, 405 sequential 113 
HIV-positive and -negative patients successfully completing treatment for PTB were recruited 114 
between February 2016 and April 2017 in urban Blantyre, Malawi. Inclusion criteria were age ≥15yrs, 115 
and successful completion of treatment for a first episode of TB as defined by the National TB Control 116 
Programme (NTP). We excluded patients who had been treated for multidrug resistant disease.  117 
Study visits were conducted within one-month of TB-treatment completion, and at 6- and 12-months 118 
thereafter. Questionnaires were completed in the local language, Chichewa. We collected data on 119 
demographics, socioeconomic situation (SES), TB and respiratory symptoms, quality of life, main 120 
occupation and income at each study visit. Patients provided information on occupation and income 121 
prior to TB illness from memory. Data on ongoing health seeking and associated direct and indirect 122 
costs were collected prospectively. Occupation was described using categories defined by the Malawi 123 
Demographic Health Survey 2015-16.(17) Income and dissaving questions were adapted from the 124 
STOP TB costing questionnaire.(18) Monthly income was defined as money received by the individual, 125 
from work or other means, and was standardised into US dollars (S1 Appendix). Socioeconomic status 126 
was defined at TB-treatment completion using the Malawi EquityTool 2012.(19) Information on TB 127 
microbiology at diagnosis was collected from NTP registers. HIV care is provided in a separate vertical 128 
programme in this setting, and patient-held health passports were therefore reviewed to ascertain 129 
HIV and ART status, with HIV testing offered to all those with unknown serostatus who had not had a 130 
documented test within the past 1-month (Serial testing with Determine 1/2™; Alere, USA / Uni-131 
Gold™; Recombigen® HIV, Trinity Biotech, Ireland). CD4 counts were measured in all HIV-positive 132 
participants.  133 
Illness narrative interviews were conducted with purposively selected patients who had completed 134 
TB-treatment ≥12-months previously, in order to explore their experiences of TB illness and 135 
recovery.(20) Recruitment ensured variation in gender, HIV status and socioeconomic status, and was 136 
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stopped at the point of saturation. Interviews were conducted in Chichewa by a Malawian research 137 
assistant in a private location of the participant’s choice, most frequently their home, using a pre-138 
designed interview guide structured around the illness trajectory (life before, during and after TB-139 
treatment), which addressed issues of health, healthcare seeking behaviour and experiences, 140 
socioeconomic wellbeing, family and community life (S2 Appendix). Interviews were audio-recorded, 141 
transcribed into Chichewa, and translated into English. Notes and observations recorded by the study 142 
team were included as primary data. 143 
All participants were compensated for their time and travel costs, in keeping with local ethics 144 
guidelines. The amount received over the 1-year study period was the equivalent of $15.30 USD per 145 
participant.  146 
Sample size 147 
The sample size of 400 was pre-determined by the parent study, in order to allow the prevalence of 148 
post-TB lung disease (PTLD) to be estimated with +/- 5% precision and 95% confidence. 149 
Data analysis 150 
Quantitative data were analysed using Stata 15 (StataCorp). Health economic parameters are 151 
presented for each time point using median (interquartile range [IQR]) values. Chi-square, Fisher’s 152 
exact or Wilcoxon rank sum tests were used for comparisons between participant groups, and 153 
McNemar’s test used for within-group comparisons over time. Individuals were classified by 154 
occupation into those with paid work (self-employed, formally employed (in government, non-155 
governmental organisations, private sector), farming, domestic work, informal piece-work), unpaid 156 
work (housework, students), and no work (retired, unemployed). Participants were considered to be 157 
living in poverty if earning <$1.90/day.(21)  158 
Logistic and linear regression models were used to explore the relationship between post-TB lung 159 
disease and economic outcomes, controlling for pre-specified covariates recorded at TB treatment 160 
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completion (age, gender, HIV status, TB microbiology, educational level). Qualitative data were 161 
analysed thematically using an inductive framework approach(22): transcripts were discussed, a 162 
coding and thematic framework was developed iteratively, relationships between codes and themes 163 
were identified manually, and emerging links were cross-checked by discussion with the study team  164 
and triangulation with study team notes.   165 
Approvals & permissions 166 
The Liverpool School of Tropical Medicine (LSTM) sponsored the study. Ethical approval was obtained 167 
from the LSTM (15.040RS) and Malawi College of Medicine Research Ethics (P.10/15/1813. 168 
P.06/17/2020) Committees. All participants provided written informed consent.  169 
 170 
  171 
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Results  172 
Patient population 173 
450 PTB survivors were screened, and 405 met inclusion criteria (Figure 1). The 37/405 (9.1%) 174 
participants who did not complete the final study visit had similar characteristics (age, sex, HIV status, 175 
TB microbiology, SES) to those  who completed the study, but lower average CD4 counts at TB 176 
treatment completion (113 cells/µL [IQR: 62-197] vs. 244 cells/µL [IQR: 137-398], p=0.007)  (S3 177 
Appendix). 178 
The majority of participants (67.9% [275/405]) were male, 77.3% (313/405) had microbiologically 179 
proven PTB disease, and 60.6% (244/403) were HIV-positive. Over half were from the lowest three 180 
urban wealth quintiles (54.3% [202/372]) and 38.0% (154/405) had not attended school beyond 181 
primary level. The 21 participants purposively selected for in-depth interviews had similar 182 
demographic and socioeconomic characteristics to other study participants, but a longer duration of 183 
illness prior to TB-treatment (13.0 vs. 8.7 weeks, p<0.001), and less formal education (38.1 [8/21] vs. 184 
63.3% [243/384] beyond primary school, p=0.021) (Table 1). 185 
Table 1: Participant characteristics for participants included/ not included in nested qualitative work (n=21) 
Participant characteristic Parent study only 
(n=384) 
Parent & qualitative 
study (n=21) 
p-value∞ 
Demographic data    
Age (yrs) (median, IQR) 34 (28 - 41) 35 (32 - 41) 0.246 
Male sex (n, %) 261 (68.0%) 14 (66.7%) 0.901 
Positive TB microbiology* at diagnosis (n, %) 299 (77.9%) 14 (66.7%) 0.233 
Self-reported illness duration prior to TB-
treatment (weeks) (median, IQR) 
8.7 (4.3 – 13.0) 13.0 (13.0 – 52.2) <0.001 
HIV-infected at TB-treatment completion (n=403)^ 232 (60.7) 12 (57.1) 0.743 
Antiretroviral treatment use at TB-treatment 
completion (n, %) (n=244) 
215 (92.7) 9 (75.0) 0.030 
CD4 if HIV-positive at TB-treatment completion 
(cells/µL) (n=242) 
229 (127  397) 214 (126 – 420) 0.941 
Maximum education level > primary school (n, %) 243 (63.3%) 8 (38.1%) 0.021 
Urban SES quin le (n=372)† 
- Poorest  
- 2nd poorest 
- Middle 
- 2nd most wealthy 
- Most wealthy 
 
21 (6.0%) 
79 (22.5%) 
87 (24.8%) 
111 (31.6%) 
53 (15.1%) 
 
1 (4.8%) 
6 (28.6%) 
8 (38.1%) 
3 (14.3%) 
3 (14.3%) 
 
0.449 
*Microbiology positive if smear, culture or Xpert MTB/RIF positive; ^HIV status missing for 2 study participants; † Urban 
household wealth quintiles calculated from household characteristic and asset data, using a tool validated by the Malawi 
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Malaria Indicator Survey 2012 (Equity measurement Toolkit; Social Franchising Metrics Working Group(19)). Missing data 
for n=33 participants; ∞Chi2 test for categorical variables, Wilcoxon rank sum test for continuous variables 
 186 
Economic morbidity, after TB-treatment completion 187 
Occupation and income 188 
The proportion of participants in paid work fell during TB disease to a nadir of 54.8% (222/405) at TB-189 
treatment completion, with 36.5% (148/405) unemployment (National unemployment rates 5.4 – 190 
5.7% between 2016-2018) (Table 2).(23) One year later, fewer participants were in paid work than 191 
prior to disease (63.0% [232/368] vs. 72.4% [293/405], p=0.003), and the proportion of self-employed 192 
business people had not returned to previous levels (pre-illness: 32.8% [133/405]; TB-treatment end 193 
26.9% [109/405]; 1-year post treatment completion 25.8% [95/368], p=0.026). Patterns were similar 194 
for HIV-positive and negative participants (Figure 2).   195 
A fifth of participants (20.7%, 74/358) moved from paid or unpaid work prior to TB disease, to no work 196 
by 1-year after TB-treatment completion. Half of these individuals lost work during TB disease and 197 
treatment (47.3%, 35/74), and half lost work in the year after treatment completion (52.7%, 39/74). 198 
Loss of work was more common in the lowest two vs. highest three socioeconomic quintiles (28.6% 199 
[30/105] vs. 15.9% [39/245], p=0.004). Amongst those who were employed prior to disease, 11.0% 200 
(17/154) had become self-employed by the end of follow-up. 201 
Many participants did not know their total household income, including 40.7% (53/130) of women. 202 
However, individual incomes followed a similar pattern to that seen with work: median income was 203 
highest prior to TB illness, falling to a nadir at TB-treatment completion, with minimal recovery in the 204 
following year (Figure 3). Monthly incomes fell by a median of $11.59 (IQR for income difference: -205 
72.20 to +12.89) from pre-illness to 1-year post treatment completion, with the greatest loss amongst 206 
those who were originally self-employed (-$74.96 [IQR: -231.99 to -7.01]). There was little difference 207 
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in the median income loss experienced by the poorest two and wealthiest three socioeconomic 208 
quintiles over this period (-$11.78 [IQR: -56.73 to +16.63] vs. -$10.77 [IQR:-77.23 to +11.60], p=0.556).  209 
The proportion of participants living in poverty increased from 41.6% (166/399) to 57.7% (211/366) 210 
over this time (p<0.001), but the proportion of participants reporting that they were the highest 211 
earner in the household did not change (pre-illness: 57.0% [231/405]; TB-treatment end 54.6% 212 
[221/405]; 1-year post treatment completion 60.6% [223/368]).  213 
Health care costs 214 
Direct health care costs in the year after TB-treatment completion were limited. Amongst those 215 
contributing any follow up data, two thirds of participants (66.8%, 254/380) had ≥1 outpatient visit, 216 
including 264 planned and 173 unscheduled visits, and 6.3% (24/380) had ≥1 inpatient admission. The 217 
majority of both outpatient visits (95.0%, 415/437) and admissions (88.9%, 24/27) occurred within the 218 
public sector. The majority of planned visits (87.1%, 230/264) were for appointments at ART clinics.  219 
The median direct cost of an outpatient visit, including both planned and unscheduled visits, was $1.05 220 
(IQR: 0.14 to 2.09), including expenditure for clinic fees and medications, and travel, accommodation, 221 
food, and phone time for patients and guardians. The median time taken for any outpatient visit was 222 
three hours (IQR: 2 to 4), and loss of income was reported for 53.1% (232/437) of these visits, with 223 
average income time loss of one hour (IQR: 0 to 1) only. Guardians attended with study participants 224 
for a minority (8.2%, 36/437) of outpatient visits, and on these occasions rarely reported income time 225 
lost (5.6%, 2/36).  226 
The median duration of the 27 inpatient admissions was four nights (IQR: 2 to 19), with median direct 227 
costs of $19.62 (IQR 13.30 to 61.91). Lost income was reported by participants for under a third of 228 
admissions (29.6%, 8/27), and although participants were accompanied by a guardian for the majority 229 
of these admissions (88.9%, 24/27) only one guardian reported lost income. 230 
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The proportion of participants attending ≥1 outpatient visit was similar in the lowest two, and top 231 
three socioeconomic quintiles (66.2% [73/107] vs. 66.8% [177/265], p=0.790), and median per-visit 232 
costs were similar between socioeconomic groups ($0.84 vs. $1.12, p=0.578). A higher proportion of 233 
participants from the lowest two socioeconomic quintiles required hospital admission compared to 234 
the top three quintiles (10.3% [11/107] vs. 4.9% [13/265], p=0.056) but median per-admission costs 235 
were similar between groups ($19.27 vs. $19.97, p=0.750).  236 
Impact of economic morbidity, on patients and households 237 
Interruption of a child’s schooling due to the financial impact of illness was reported by 17.0% (69/405) 238 
and 9.5% (35/368) of TB-affected households in the years prior to and after TB-treatment completion, 239 
respectively. School interruptions were more common in the lowest two, compared to the top three, 240 
socioeconomic quintiles (32.1% [34/106] vs. 17.7% [45/255], p=0.003).  241 
Over a third of participants (37.0%, 150/405) reported that TB had had a severe financial impact on 242 
their household, graded ≥4/5 on a Likert scale, at TB-treatment completion. This proportion was 16.9% 243 
(62/368) 1-year later. Self-reported severe financial impact was more common in the lower 244 
socioeconomic strata (58.5% [62/106] vs. 37.4% [96/257], p<0.001). 245 
Almost three quarters of participants reported dissaving by the point of TB-treatment completion 246 
(73.6%, 298/405), and half reported dissaving in the following year (50.5%, 186/368), at values of 247 
54.9% (IQR:24.3 to 146.4%) and 53.2% (IQR:19.0 to 125.7%) of the baseline monthly income prior to 248 
TB illness respectively. Over a quarter (26.7%, 27/101) of those with no dissaving during TB disease 249 
and treatment did go on to report dissaving in the year after treatment completion. Dissaving was 250 
more common in lower SES quintiles, but with lower absolute and relative values (Table 2).  251 
Table 2: Prevalence of dissaving in the years prior to and after TB-treatment completion, stratified by wealth quintiles, and 
standardised into USD or by pre-TB individual income with median(IQR) values given # 
Time period 
Malawi urban wealth quintile (Q1 - Q5)* 
All 
participants* Q1  (n=56) 
Wealthiest 
Q2 (n=114) Q3 (n=95) Q4 (n=85) 
Q5 (n=22) 
Poorest 
Prior to TB illness (n=372) 
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Pre-disease monthly income 
(USD)  
108.30  
(0 – 270.76) 
83.03  
(39.71 – 
287.73) 
63.18  
(25.27 – 
158.84) 
61.37  
(25.27 – 
111.91) 
41.52  
(10.83 – 
121.30) 
72.20  
(25.27 – 
173.29) 
During TB illness and treatment (n=372) 
Proportion incurring any 
dissaving 
28 / 56 
(50.0%) 
83/ 114 
(72.8%) 
75 / 95 
(79.0%) 
68 / 85 
(80.0%) 
20 / 22 
(90.9%) 
274/372 
(73.7%) 
Value of dissaving, if 
experienced  (USD)** 
166.9  
(94.58 – 
423.50) 
69.54 
(34.77 – 
173.85) 
38.94 
(15.30 – 
115.44) 
27.82 
(16.69 – 
80.95) 
33.38 
(13.91 – 
100.39) 
55.63 
(20.86 – 
139.08) 
% of pre-disease monthly 
income 
89.2%  
(34.1 – 266.0) 
58.2% 
(24.1 –152.3) 
53.9% 
(20.7 – 
111.2) 
41.6% 
(23.4 – 
104.6) 
44.1% 
(35.0 – 173.4) 
54.9% 
(24.3 – 146.4) 
Year after TB-treatment completion (n=360) 
Proportion incurring any 
dissaving 
12 /55 
(21.8%) 
48 / 107 
(44.9%) 
61 / 92 
(66.3%) 
50 / 84 
(59.5%) 
13 / 22  
(59.1%) 
184/ 360 
(51.1%) 
Value of dissaving, if 
experienced  (USD)** 
167.6  
(59.36 – 
272.35) 
69.83 
(24.1 –152.3) 
39.11 
(20.95 – 
92.18) 
37.71 
(13.97 – 
69.83) 
20.95 
(11.17 – 
31.42) 
41.9 
(20.95 – 
94.97) 
% of pre-disease monthly 
income 
112.5%  
(49.0 – 232.1) 
77.6% 
(19.0 – 
198.7) 
59.3% 
(24.2 – 89.3) 
41.9% 
(13.6 – 
120.7) 
29% 
(15.0 – 58.0) 
53.2% 
(19.0 – 125.7) 
#Values given for those who experienced dissaving, only;  
*Baseline SES missing for 33 participants – data included for 372 participants only;  
**Standardisation into USD using exchange rates at mid-points of first and last study visits 
 
 
Patterns of dissaving varied by SES group, and over time (Figure 4). All wealth strata used savings 252 
during the period of TB illness and treatment, but only the wealthiest quintiles used savings during 253 
the subsequent year. Borrowing money was most common amongst lower socioeconomic strata, and 254 
over half of those in the lowest quintiles reported borrowing money in the year after TB-treatment 255 
completion. The most common sources of borrowed money were friends (44.8%, 172/384), family 256 
(26.8%, 103/384), and the black market (10.2%, 39/348) – use of the latter increased from 10.7% 257 
(19/177) in the first year to 17.1% (25/246) in the second year.  The sale of assets to cover costs due 258 
to illness during the period of TB illness and treatment was also more common in poorer groups. The 259 
most common items sold were household items (35.0%, 134/383) and mobile phones (10.7%, 41/383). 260 
Potentially income-generating assets sold included land (1.3%, 5/383), livestock (3.7%, 14/383), and 261 
means of transport (4.7%, 18/383).  262 
Relationship with TB-retreatment 263 
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TB-retreatment was initiated in 15/405 (3.7%) of participants, of whom five died, one relocated, and 264 
nine completed study follow-up. Socioeconomic outcomes were worse amongst those who survived 265 
and completed follow-up: by one year after TB-treatment completion, a higher proportion of those 266 
receiving retreatment had lost work (33.3% [3/9] vs. 20.3% [71/349], p=0.342), experienced dissaving 267 
(100% [9/9] vs. 79.4% [285/359], p=0.128), or reported a severe financial impact from TB disease 268 
(33.3% [3/9] vs. 16.4% [59/359], p=0.181), compared to those who did not receive retreatment. 269 
However, none of these differences were statistically significant. 270 
Relationship between physical and economic morbidity 271 
Almost a third of participants had abnormal spirometry (30.7%, 103/336) or regular respiratory 272 
symptoms (30.7%, 113/368) 1-year after TB treatment completion. Those with abnormal spirometry 273 
were more likely to have lost work in the period from TB-illness onset, compared to those with normal 274 
spirometry (OR 1.87, 95% CI: 1.02 to 3.41). Those with residual symptoms were more likely to report 275 
that TB had had a severe financial impact on the household, compared to those without symptoms 276 
(2.02, 95% CI: 1.10 to 3.68). Those with chest symptoms limiting their ability to keep up with peers 277 
(17.4%, 64/368), interfering with work (12.2% , 45/368), or limiting activities (4.4%, 16/368) at 1-year 278 
were significantly more likely to have experienced both of these outcomes. No significant association 279 
was observed between these measures of physical morbidity and the use of dissaving or change in 280 
income from pre illness to 1-year post TB-treatment completion (Table 3).  281 
  282 
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Table 3: Adjusted odds ratios for associations between respiratory morbidity and economic outcomes over the study 
period / at 1-year post treatment completion, in separate multivariate analyses controlling for pre-specified covariates 
recorded at TB treatment completion (age, gender, HIV status, baseline TB microbiology, educational level) 
Physical morbidity Economic outcome from prior to TB illness, to 1-year post treatment completion 
Loss of work (OR, 
95% CI) 
Use of dissaving 
(OR, 95% CI) 
Income difference (β-
coefficient, 95% CI) 
Self reported severe 
financial impact of TB 
at 1-year  (OR, 95% 
CI) 
Abnormal spirometry at 1-
year  
- No 
- Yes 
 
 
1.0 
1.87 (1.02 – 3.41) 
 
 
1.0 
1.31 (0.71 – 2.43) 
 
 
11.64 (-50.80 – 74.09) 
 
 
1.0 
1.85 (0.96 – 3.58) 
p= 0.042 p=0.393 p=0.714 p=0.066 
Respiratory symptoms at 1-
year  
- No 
- Yes 
 
 
1.0 
1.26 (0.72 – 2.20) 
 
 
1.0 
0.79 (0.45 – 1.37) 
 
 
-6.34 (-63.01 – 50.33) 
 
 
1.0 
2.02 (1.10 – 3.68) 
p=0.412 p=0.399 p=0.826 p=0.022 
Difficulty keeping up with 
peers when walking at 1-year  
- No 
- Yes 
 
 
1.0 
2.39 (1.27 – 4.49) 
 
 
1.0 
0.61 (0.32 – 1.18) 
 
 
7.26 (-62.80 – 77.31) 
 
 
1.0 
2.04 (1.03 – 4.04) 
p=0.007 p=0.145 p=0.839 p=0.041 
Chest symptoms interfering 
with / stopping work at 1-
year  
- No  
- Yes 
 
 
 
1.0 
4.13 (2.06 – 8.28) 
 
 
 
1.0 
1.04 (0.45 – 2.39) 
 
 
 
32.73 (-47.09 – 
112.56) 
 
 
 
1.0 
4.24 (2.08 – 8.66) 
p<0.001 p=0.934 p=0.421 p<0.001 
Chest symptoms limiting 
most / all daily activities at 1-
year  
- No 
- Yes 
 
 
 
1.0 
9.35 (3.02 – 28.95) 
 
 
 
1.0 
0.56 (0.17 – 1.85) 
 
 
 
12.51 (-118/28 – 
143.29) 
 
 
 
1.0 
11.82 (3.74 – 37.33) 
p<0.001 p=0.340 p=0.851 p<0.001 
Income difference: USD standardised change in monthly income from prior to TB disease, to 1-year post TB treatment 
completion; Use of dissaving: any use of savings, borrowing of money, or selling of assets from the onset of TB disease to 1-
uear post TB-treatment completion; Loss of work: No longer working, having been in work (employed or self-employed) 
prior to TB disease (Chi2 test) 
 
Illness narratives 283 
The persistent socioeconomic impact of TB disease was evident in the illness narrative data (Table 4). 284 
The shift to a lower standard of living after TB disease was raised as a barrier to ongoing health and 285 
wellbeing. The need for further dissaving and withdrawal of children from school to release extra 286 
funds were highlighted as areas of concern. 287 
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Anxiety around loss of financial security, debt, and the challenge of ongoing dependence on family 288 
and friends for support emerged as strong themes. A gendered response was seen with a perceived 289 
loss of social standing due to this dependence particularly common and problematic for men. 290 
Reasons for limited recovery of income and work were explored. Ongoing physical morbidity was 291 
noted as a challenge to patients’ livelihoods, however participants largely continued to work despite 292 
residual symptoms in order to maintain income. Stigma was widely experienced and resulted in 293 
delayed return to work, or loss of work for those previously employed, with discrimination from 294 
colleagues often rooted in the perception that TB and HIV disease are linked. Loss of business 295 
infrastructure and the lack of capital to rebuild and re-invest was highlighted. Participants reported 296 
challenges in rebuilding business relationships which had been lost after a prolonged absence during 297 
the illness period, including those with employers, employees and customers.  298 
Table 4: Quotes from in-depth interviews with TB survivors 
Theme Quote 
Impact of TB-related financial hardship on participants & households 
Reduced standard of 
living 
“Since the time I was diagnosed with TB until now, I am staying in a bad looking house, with 
bad sleeping environment along with bad food” (Female participant, 39yrs) 
 
“As [name of participant] hasn’t been able to find work since he completed his treatment, 
the family had to move up the hill, where housing is cheaper. They also had to sell most of 
their furniture. There was only a mat on the floor, a little stool and a couple of mugs for a 
family of four…Another interesting observation we made relates to his relocation. Moving 
to cheaper accommodation on top of the hill means that he leaves the house less, as physical 
exercise remains a big challenge for him. This in turn limits his occupational activities and 
affects his health seeking behavior” (Research assistant, relating to male participant, 32yrs) 
 
Anxiety around debt and 
financial insecurity 
“I never used to have financial difficulties. Now, my business is just so small with borrowed 
capital and the creditors keep coming to my house, saying they want their money. If I fail to 
pay, there will be bigger interest. I have been in debts ever since I completed the treatment 
[…]”(Female participant, 29yrs) 
 
“Now, I am not having anything to eat and sometimes I don’t have money to pay for rent. 
For example, I haven’t paid rent yet. In the past, before I became sick, I could pay rent in 
advance” (Male participant, 34yrs)  
 
“I have been facing financial challenges, lack of food and so on. In 2016, my girl failed to 
write her form two exams, due to lack of schooling that I couldn’t pay for. So, I have faced 
so many difficulties from the time that I was diagnosed with TB until now” (Female 
participant, 39yrs) 
 
“I used to sell our house equipment to sustain my family. So, we sold our TV and some small 
items. Others who could help us were living far from us and they can’t just be helping you 
every day. Our children stopped going to school, so we had to sell whatever household 
equipment we had to sustain our living” (Male participant, 32yrs) 
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Dependence on others “As of now, I have difficulties to get food, but I do try my level best to hunt for money to buy 
the food. My family supports me since I’ve completed treatment. Whenever I say that I don’t 
have money to pay rental expenses and to buy food, they do send me the money” (Female 
participant, 27yrs) 
 
Loss of social standing “While I was sick and during the time when I completed my treatment people were not 
respecting me, but people were respecting me before I became unwell with TB. I think this 
is because I lost my income, and my family helps me. When you have money, people tend to 
respect you” (Male participant, 34yrs) 
 
“He feels, once you have money, you have so much power and you can tell your employees 
what to do. In his case, his employees overtook power while he got sick, which still affects 
him” (Research assistant, relating to a male participant, 34yrs) 
 
Another male participant replied, when asked about how the income loss affects his life: “It 
has affected me a lot. I just feel depressed and sometimes I wonder if I am the same person”. 
(Male participant, 18yrs) 
 
Barriers to income recovery 
Ongoing physical 
morbidity 
“There are so many problems, I am facing these days because everything needs money. […] 
I still need to work, so I do some piece work, whether it means that I am still feeling pain, 
but I do work in order to get money to help myself […] The most important thing is to get 
money, so if you don’t work then you have to do business in order to maintain your health 
and to fulfil your needs” (Male participant, 37yrs) 
 
Stigma “My boss said that I should wait at home during treatment […]. My boss accepted my TB 
diagnosis, but she didn’t want me back after I completed” (Female participant, 42yrs). 
 
“I went back to my work, but my boss discriminated against me and he told me that he 
wouldn’t be helping me anymore financially, so I am just staying here at home” (Male 
participant, 32yrs) 
 
“They [colleagues] would be surprised to see my work performance, which was dropping as 
I could sometimes work well one day and sometimes, I could not work well […] they were 
saying that it was AIDS” (Male participant, 18yrs) 
 
“The wife of the participant told us that she sells food items in front of the house and noted 
that some people don’t want to buy from her, because they know that her husband is sick 
(Research assistant, relating to male participant, 32yrs) 
 
Loss of social and work 
relationships 
“Our customers really had forgotten us, so I think it will take time for me to grow the business 
again” (Male participant, 33yrs) 
 
Lack of capital for re-
investment 
“My life has changed now […] I have little capital […] I don’t do hard work now, so my 
employees help me do business. My business isn’t the way it was before, because some of 
my business centers are closed now, I stopped selling Irish potatoes, I closed my take-away 
shops and I only have one bench of chips […] (Male participant, 48yrs) 
 
“The TB symptoms affected my business so much, to the extent that it went down up to date 
and it’s not at all growing, though I was cured […]. My husband cannot even afford to give 
me MK 20,000.00 to start up a new business. I went to borrow money from someone on 
interest, but I haven’t paid the person back. The capital you have determines what kind of 
business one engages in. So, instead of starting up a business with the little money 
borrowed, you start buying maize to feed children at home” (Female participant, 39yrs) 
 
 
 299 
  300 
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Discussion  301 
In this study we explore the long-term socioeconomic consequences of TB disease after TB-treatment 302 
completion. Our data show that the substantial financial insult experienced during TB illness extends 303 
to 12-months post-treatment completion. Economic recovery in the year after TB-treatment was slow 304 
and incomplete, with many patients continuing to experience income loss and reduced work. 305 
Persistent dissaving was widely observed and suggests increasing financial vulnerability. A substantial 306 
minority of patients experienced ongoing respiratory morbidity after treatment completion, and this 307 
was significantly associated with economic morbidity. Additional barriers to recovery after TB 308 
treatment completion included ongoing financial insecurity from initial TB disease, reduced social 309 
capital, and TB-related stigma.  310 
Even in settings where TB services are free of charge within the public sector, the financial impact of 311 
TB disease is marked: a 2014 systematic review of 49 studies found that on average patients lost the 312 
equivalent of 58% (range 5-306%) of annual individual income and 39% (range 4-148%) of annual 313 
household income in direct and indirect costs during TB illness and treatment, with half of all costs 314 
incurred prior to treatment initiation.(3) Those incurring ‘catastrophic’ costs  (≥20% of annual 315 
household income) have been shown to have higher odds of adverse TB-treatment outcomes (death, 316 
treatment failure, or recurrence).(4)  317 
Our results support these findings of a major initial TB related financial insult: during TB disease and 318 
treatment employment decreased, average patient incomes fell, and three quarters of the cohort 319 
incurred dissaving. This pattern was seen across socioeconomic and employment groups, and by the 320 
end of TB-treatment the majority of TB survivors were living in poverty.  321 
However, our data also show that this impact is sustained, even after TB-treatment completion. 322 
Although the proportion of participants working increased in the year after TB-treatment completion, 323 
it did not return to baseline: 1-year after TB-treatment almost a third of patients were unemployed, 324 
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with standardised individual incomes lower than prior to illness. Self-employed individuals appeared 325 
particularly vulnerable, with large drops in income experienced by both those who were in work 326 
through their disease, as well as those who stopped working.  327 
Post-TB physical morbidity was associated with limited recovery: abnormal spirometry, ongoing 328 
respiratory symptoms, and chest symptoms limiting activity at 1-year were strongly associated with 329 
loss of work and perceived financial severity of the TB illness episode in multivariate analyses. Post-TB 330 
physical morbidity is increasingly recognised as a key component of the overall number of Disability- 331 
and Quality-Adjusted Life Years lost in relation to TB disease,(24) and our findings suggests that its 332 
impact on long-term productivity and financial vulnerability should also be considered.(25) Recurrent 333 
TB disease may also be detrimental to this group: socioeconomic outcomes amongst those receiving 334 
TB retreatment were poor in this study, but our ability to explore this finding was limited by the low 335 
numbers of retreatment patients identified, and further work is needed in this area.  336 
In-depth interviews highlighted the loss of business assets during disease, with limited access to 337 
capital to rebuild after treatment completion as a major barrier to recovery. The challenge of 338 
rebuilding relationships with employers, employees and clients was emphasised, and attributed to a 339 
prolonged period of absence during TB illness and treatment, as well as loss of social standing due to 340 
impoverishment, disability, and the direct consequences of TB and HIV related stigma. The impact of 341 
TB-related stigma on patients’ emotional wellbeing has been documented elsewhere,(26) but our data 342 
suggest that this also has socioeconomic repercussions. 343 
Rather than promptly recovering, our data suggest that many TB survivors are at risk of further 344 
financial and psychological decline after TB-treatment completion. Dissaving is a coping mechanism 345 
for catastrophic costs,(2) and has been widely observed in TB-affected households during TB illness 346 
and treatment.(27) However in this study, dissaving was observed in half of the cohort in the year 347 
after TB-treatment completion, including several households who had resisted dissaving during initial 348 
disease and treatment itself. Concern about dissaving was widely reported in the qualitative data. 349 
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These finding suggest that even after TB-treatment completion, households continue to deplete their 350 
reserves or enter into further debt as they struggle to cover costs or seek to rebuild their lives and 351 
livelihoods.  352 
Of particular concern, both the use of savings and the sale of assets declined in the post-treatment 353 
period, particularly amongst low socioeconomic strata, perhaps reflecting depletion of these 354 
resources. Instead, borrowing of money remained widespread with increasing use of the black market 355 
for loans, perhaps reflecting the exhaustion of more ‘benign’ sources of loans such as friends and 356 
family.  357 
Interruption of children’s education continued in 10% of households in the year after TB-treatment 358 
completion, and a high burden of anxiety related to financial insecurity, lower standard of living, and 359 
school interruptions was observed amongst TB survivors. Men voiced concern around loss of social 360 
standing, which is consistent with previous work describing high societal pressures on men to be 361 
effective providers, regardless of the difficulties of their circumstances.(28) Taken together, our 362 
qualitative and quantitative data suggest that TB disease may push patients into an ongoing cycle of 363 
poverty, with many patients become increasingly financially vulnerable after TB-treatment 364 
completion, rather than experiencing financial recovery.   365 
 366 
This study was performed at a single site and work from other resource-limited settings is needed to 367 
confirm findings. In the absence of a control group we cannot exclude the possibility that changes 368 
observed were related to general changes in the economy, although this is unlikely as unemployment 369 
within Malawi was falling over the study period, changes in income persisted despite time-dependant 370 
standardisation into USD, and findings were consistent across qualitative and quantitative data.(23) 371 
Data on incomes and occupation prior to TB-illness onset, and health care costs between study visits 372 
were collected retrospectively, with some risk of recall bias. Our analyses used individual rather than 373 
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household level income data, perhaps leading us to underestimate participants’ access to financial 374 
resources. The financial compensation provided for study participation may have acted as an 375 
additional source of income, cushioning participants from the full financial hardship which may have 376 
been experienced under routine conditions.  377 
Strengths of this study include its novel focus on patients’ lives and livelihoods after TB-treatment 378 
completion, and use of mixed methods to understand participant perspectives and experiences. 379 
Qualitative data were collected to saturation, and the economic tools used were derived from 380 
validated sources. The study was conducted in an unselected population, with broad inclusion criteria, 381 
and minimal loss to follow-up, allowing broad generalisability.  382 
 383 
Our findings have several key implications for TB research, policy and programmes. We recommend 384 
that studies investigating costs associated with TB disease should measure economic outcomes 385 
beyond TB-treatment completion. Recent data suggest that mortality amongst TB survivors is higher 386 
than that of TB-naïve individuals, and the extent to which the socioeconomic impact of TB disease 387 
contributes to this requires further investigation. Our findings suggest that interventions to protect 388 
livelihoods and prevent dissaving during disease may be crucial to the long-term wellbeing of TB-389 
affected households.  Microloans and training programmes to assist TB survivors to rebuild their 390 
livelihoods after treatment completion must be explored. These interventions should be co-developed 391 
with TB-affected communities, and must be accompanied by community level education programmes 392 
to address TB-related stigma. Ultimately, a renewed focus on physical, psychological, and 393 
socioeconomic wellbeing after TB-treatment completion is needed if we are to improve the long-term 394 
outcomes of TB survivors.  395 
  396 
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